Prednisolone maintenance therapy in pemphigus vulgaris.
Phase 3
- Conditions
- Pemphigus vulgaris.Pemphigus vulgarisL10.0
- Registration Number
- IRCT20190813044524N1
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Pemphigus vulgaris patients on remission phase.
Under treatment with low dose prednisolone (5-10 mg/day) maintenance therapy.
Positive anti-desmogleion 1 and/or 3.
Exclusion Criteria
Pemphigus vulgaris patients with negative anti-desmogleion.
Active phase of the disease
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Continuation of the remission phase of the disease. Timepoint: Before starting the study,Every three months, End of the first year. Method of measurement: Direct examination by the a dermatologist so that the patient has no skin and/or mucosal manifestations.
- Secondary Outcome Measures
Name Time Method